Pay in 4 interest-free payments of $7.44 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
8 weeks 1 vial Covers full titration through 0.5 mg (Weeks 1-8 uses about 3 mg total
Compound Overview Tirzepatide is a first-in-class dual incretin receptor agonist that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors
Creatine causes 1-3 kg of intracellular water retention in muscle tissue
Peptide Cycling Prevents Receptor Desensitization Just like insulin receptors can become resistant with constant sugar exposure, peptide receptors downregulate if overstimulated
Tapering can make the transition more gradual, give your body more time to adjust, and help you focus on lifestyle changes to support weight and blood sugar control
Common Side Effects The most frequently reported side effects include: Nausea Vomiting Diarrhea Constipation Abdominal pain Decreased appetite These gastrointestinal symptoms often lessen over time as the body adjusts to the medication
